X-ray-visible microcapsules containing mesenchymal stem cells improve hind limb perfusion in a rabbit model of peripheral arterial disease

Dorota Kedziorek, Lawrence V. Hofmann, Yingli Fu, Wesley D. Gilson, Kenyatta M. Cosby, Bernard Kohl, Brad P. Barnett, Brian W. Simons, Piotr Walczak, Jeff W Bulte, Kathleen L Gabrielson, Dara Kraitchman

Research output: Contribution to journalArticle

Abstract

The therapeutic goal in peripheral arterial disease (PAD) patients is to restore blood flow to ischemic tissue. Stem cell transplantation offers a new avenue to enhance arteriogenesis and angiogenesis. Two major problems with cell therapies are poor cell survival and the lack of visualization of cell delivery and distribution. To address these therapeutic barriers, allogeneic bone marrow-derived mesenchymal stem cells (MSCs) were encapsulated in alginate impregnated with a radiopaque contrast agent (MSCXcaps.) In vitro MSC-Xcap viability by a fluorometric assay was high (96.9% ± 2.7% at 30 days postencapsulation) and as few as 10 Xcaps were visible on clinical x-ray fluoroscopic systems. Using an endovascular PAD model, rabbits (n = 21) were randomized to receive MSC-Xcaps (n = 6), empty Xcaps (n = 5), unencapsulated MSCs (n = 5), or sham intramuscular injections (n = 5) in the ischemic thigh 24 hours postocclusion. Immediately after MSC transplantation and 14 days later, digital radiographs acquired on a clinical angiographic system demonstrated persistent visualization of the Xcap injection sites with retained contrast-to-noise. Using a modified TIMI frame count, quantitative angiography demonstrated a 65% improvement in hind limb perfusion or arteriogenesis in MSC-Xcap-treated animals versus empty Xcaps. Post-mortem immunohistopathology of vessel density by anti-CD31 staining demonstrated an 87% enhancement in angiogenesis in Xcap-MSC-treated animals versus empty Xcaps. MSC-Xcaps represent the first x-ray-visible cellular therapeutic with enhanced efficacy for PAD treatment.

Original languageEnglish (US)
Pages (from-to)1286-1296
Number of pages11
JournalStem Cells
Volume30
Issue number6
DOIs
StatePublished - Jun 2012

Fingerprint

Peripheral Arterial Disease
Mesenchymal Stromal Cells
Capsules
Extremities
Perfusion
X-Rays
Rabbits
Cell Survival
Mesenchymal Stem Cell Transplantation
Intramuscular Injections
Stem Cell Transplantation
Therapeutics
Cell- and Tissue-Based Therapy
Thigh
Contrast Media
Noise
Angiography
Bone Marrow
Staining and Labeling
Injections

Keywords

  • Angiogenesis inducing agents
  • Barium sulfate
  • Cone-beam computed tomography
  • Mesenchymal stem cells
  • Peripheral arterial disease

ASJC Scopus subject areas

  • Cell Biology
  • Developmental Biology
  • Molecular Medicine

Cite this

X-ray-visible microcapsules containing mesenchymal stem cells improve hind limb perfusion in a rabbit model of peripheral arterial disease. / Kedziorek, Dorota; Hofmann, Lawrence V.; Fu, Yingli; Gilson, Wesley D.; Cosby, Kenyatta M.; Kohl, Bernard; Barnett, Brad P.; Simons, Brian W.; Walczak, Piotr; Bulte, Jeff W; Gabrielson, Kathleen L; Kraitchman, Dara.

In: Stem Cells, Vol. 30, No. 6, 06.2012, p. 1286-1296.

Research output: Contribution to journalArticle

Kedziorek, Dorota ; Hofmann, Lawrence V. ; Fu, Yingli ; Gilson, Wesley D. ; Cosby, Kenyatta M. ; Kohl, Bernard ; Barnett, Brad P. ; Simons, Brian W. ; Walczak, Piotr ; Bulte, Jeff W ; Gabrielson, Kathleen L ; Kraitchman, Dara. / X-ray-visible microcapsules containing mesenchymal stem cells improve hind limb perfusion in a rabbit model of peripheral arterial disease. In: Stem Cells. 2012 ; Vol. 30, No. 6. pp. 1286-1296.
@article{b6e220a1e2d8440fb784b36264492029,
title = "X-ray-visible microcapsules containing mesenchymal stem cells improve hind limb perfusion in a rabbit model of peripheral arterial disease",
abstract = "The therapeutic goal in peripheral arterial disease (PAD) patients is to restore blood flow to ischemic tissue. Stem cell transplantation offers a new avenue to enhance arteriogenesis and angiogenesis. Two major problems with cell therapies are poor cell survival and the lack of visualization of cell delivery and distribution. To address these therapeutic barriers, allogeneic bone marrow-derived mesenchymal stem cells (MSCs) were encapsulated in alginate impregnated with a radiopaque contrast agent (MSCXcaps.) In vitro MSC-Xcap viability by a fluorometric assay was high (96.9{\%} ± 2.7{\%} at 30 days postencapsulation) and as few as 10 Xcaps were visible on clinical x-ray fluoroscopic systems. Using an endovascular PAD model, rabbits (n = 21) were randomized to receive MSC-Xcaps (n = 6), empty Xcaps (n = 5), unencapsulated MSCs (n = 5), or sham intramuscular injections (n = 5) in the ischemic thigh 24 hours postocclusion. Immediately after MSC transplantation and 14 days later, digital radiographs acquired on a clinical angiographic system demonstrated persistent visualization of the Xcap injection sites with retained contrast-to-noise. Using a modified TIMI frame count, quantitative angiography demonstrated a 65{\%} improvement in hind limb perfusion or arteriogenesis in MSC-Xcap-treated animals versus empty Xcaps. Post-mortem immunohistopathology of vessel density by anti-CD31 staining demonstrated an 87{\%} enhancement in angiogenesis in Xcap-MSC-treated animals versus empty Xcaps. MSC-Xcaps represent the first x-ray-visible cellular therapeutic with enhanced efficacy for PAD treatment.",
keywords = "Angiogenesis inducing agents, Barium sulfate, Cone-beam computed tomography, Mesenchymal stem cells, Peripheral arterial disease",
author = "Dorota Kedziorek and Hofmann, {Lawrence V.} and Yingli Fu and Gilson, {Wesley D.} and Cosby, {Kenyatta M.} and Bernard Kohl and Barnett, {Brad P.} and Simons, {Brian W.} and Piotr Walczak and Bulte, {Jeff W} and Gabrielson, {Kathleen L} and Dara Kraitchman",
year = "2012",
month = "6",
doi = "10.1002/stem.1096",
language = "English (US)",
volume = "30",
pages = "1286--1296",
journal = "Stem Cells",
issn = "1066-5099",
publisher = "AlphaMed Press",
number = "6",

}

TY - JOUR

T1 - X-ray-visible microcapsules containing mesenchymal stem cells improve hind limb perfusion in a rabbit model of peripheral arterial disease

AU - Kedziorek, Dorota

AU - Hofmann, Lawrence V.

AU - Fu, Yingli

AU - Gilson, Wesley D.

AU - Cosby, Kenyatta M.

AU - Kohl, Bernard

AU - Barnett, Brad P.

AU - Simons, Brian W.

AU - Walczak, Piotr

AU - Bulte, Jeff W

AU - Gabrielson, Kathleen L

AU - Kraitchman, Dara

PY - 2012/6

Y1 - 2012/6

N2 - The therapeutic goal in peripheral arterial disease (PAD) patients is to restore blood flow to ischemic tissue. Stem cell transplantation offers a new avenue to enhance arteriogenesis and angiogenesis. Two major problems with cell therapies are poor cell survival and the lack of visualization of cell delivery and distribution. To address these therapeutic barriers, allogeneic bone marrow-derived mesenchymal stem cells (MSCs) were encapsulated in alginate impregnated with a radiopaque contrast agent (MSCXcaps.) In vitro MSC-Xcap viability by a fluorometric assay was high (96.9% ± 2.7% at 30 days postencapsulation) and as few as 10 Xcaps were visible on clinical x-ray fluoroscopic systems. Using an endovascular PAD model, rabbits (n = 21) were randomized to receive MSC-Xcaps (n = 6), empty Xcaps (n = 5), unencapsulated MSCs (n = 5), or sham intramuscular injections (n = 5) in the ischemic thigh 24 hours postocclusion. Immediately after MSC transplantation and 14 days later, digital radiographs acquired on a clinical angiographic system demonstrated persistent visualization of the Xcap injection sites with retained contrast-to-noise. Using a modified TIMI frame count, quantitative angiography demonstrated a 65% improvement in hind limb perfusion or arteriogenesis in MSC-Xcap-treated animals versus empty Xcaps. Post-mortem immunohistopathology of vessel density by anti-CD31 staining demonstrated an 87% enhancement in angiogenesis in Xcap-MSC-treated animals versus empty Xcaps. MSC-Xcaps represent the first x-ray-visible cellular therapeutic with enhanced efficacy for PAD treatment.

AB - The therapeutic goal in peripheral arterial disease (PAD) patients is to restore blood flow to ischemic tissue. Stem cell transplantation offers a new avenue to enhance arteriogenesis and angiogenesis. Two major problems with cell therapies are poor cell survival and the lack of visualization of cell delivery and distribution. To address these therapeutic barriers, allogeneic bone marrow-derived mesenchymal stem cells (MSCs) were encapsulated in alginate impregnated with a radiopaque contrast agent (MSCXcaps.) In vitro MSC-Xcap viability by a fluorometric assay was high (96.9% ± 2.7% at 30 days postencapsulation) and as few as 10 Xcaps were visible on clinical x-ray fluoroscopic systems. Using an endovascular PAD model, rabbits (n = 21) were randomized to receive MSC-Xcaps (n = 6), empty Xcaps (n = 5), unencapsulated MSCs (n = 5), or sham intramuscular injections (n = 5) in the ischemic thigh 24 hours postocclusion. Immediately after MSC transplantation and 14 days later, digital radiographs acquired on a clinical angiographic system demonstrated persistent visualization of the Xcap injection sites with retained contrast-to-noise. Using a modified TIMI frame count, quantitative angiography demonstrated a 65% improvement in hind limb perfusion or arteriogenesis in MSC-Xcap-treated animals versus empty Xcaps. Post-mortem immunohistopathology of vessel density by anti-CD31 staining demonstrated an 87% enhancement in angiogenesis in Xcap-MSC-treated animals versus empty Xcaps. MSC-Xcaps represent the first x-ray-visible cellular therapeutic with enhanced efficacy for PAD treatment.

KW - Angiogenesis inducing agents

KW - Barium sulfate

KW - Cone-beam computed tomography

KW - Mesenchymal stem cells

KW - Peripheral arterial disease

UR - http://www.scopus.com/inward/record.url?scp=84861902472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861902472&partnerID=8YFLogxK

U2 - 10.1002/stem.1096

DO - 10.1002/stem.1096

M3 - Article

C2 - 22438076

AN - SCOPUS:84861902472

VL - 30

SP - 1286

EP - 1296

JO - Stem Cells

JF - Stem Cells

SN - 1066-5099

IS - 6

ER -